These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9614963)

  • 21. Evolving concepts in the systemic adjuvant treatment of breast cancer.
    Bonadonna G
    Cancer Res; 1992 Apr; 52(8):2127-37. PubMed ID: 1559216
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients].
    Sack H
    Strahlenther Onkol; 1995 Jun; 171(6):360-1. PubMed ID: 7597623
    [No Abstract]   [Full Text] [Related]  

  • 24. Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients.
    Mouridsen HT; Rose C; Brincker H; Thorpe SM; Rank F; Fischerman K; Andersen KW
    Recent Results Cancer Res; 1984; 96():117-28. PubMed ID: 6396765
    [No Abstract]   [Full Text] [Related]  

  • 25. Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer.
    Hartman AR; Fleming GF; Dillon JJ
    Clin Breast Cancer; 2001 Jul; 2(2):138-43; discussion 144. PubMed ID: 11899785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can biology trump anatomy? Do all node-positive patients with breast cancer need chemotherapy?
    Henry NL; Hayes DF
    J Clin Oncol; 2007 Jun; 25(18):2501-3. PubMed ID: 17577024
    [No Abstract]   [Full Text] [Related]  

  • 27. Postmenopausal node-positive comparison of observation with CMFP and CMPF + tamoxifen adjuvant therapy: an Eastern Cooperative Oncology Group trial.
    Tormey DC; Taylor SG; Gray R; Olson JE
    Recent Results Cancer Res; 1984; 96():110-6. PubMed ID: 6396764
    [No Abstract]   [Full Text] [Related]  

  • 28. [Benefits of adjuvant chemotherapy for breast cancer].
    Motomura K; Noguchi S; Inaji H; Koyama H
    Gan To Kagaku Ryoho; 1997 Aug; 24(10):1239-44. PubMed ID: 9279342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
    Kimura M; Tominaga T; Takatsuka Y; Toi M; Abe R; Koyama H; Takashima S; Nomura Y; Miura S; Kimijima I; Tashiro H; Ohashi Y;
    Breast Cancer; 2010 Jul; 17(3):190-8. PubMed ID: 19575284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized cooperative study of perioperative chemotherapy in breast cancer.
    Sertoli MR; Bruzzi P; Pronzato P; Queirolo P; Amoroso D; Del Mastro L; Venturini M; Vigani A; Bertelli G; Campora E
    J Clin Oncol; 1995 Nov; 13(11):2712-21. PubMed ID: 7595729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.
    Pagani O; Gelber S; Simoncini E; Castiglione-Gertsch M; Price KN; Gelber RD; Holmberg SB; Crivellari D; Collins J; Lindtner J; Thürlimann B; Fey MF; Murray E; Forbes JF; Coates AS; Goldhirsch A;
    Breast Cancer Res Treat; 2009 Aug; 116(3):491-500. PubMed ID: 18953651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study.
    Bianco AR; De Placido S; Gallo C; Pagliarulo C; Marinelli A; Petrella G; D'Istria M; Delrio G
    Lancet; 1988 Nov; 2(8620):1095-9. PubMed ID: 2903322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant systemic therapy in postoperative node-positive patients with breast carcinoma: the CALGB trial and the ECOG premenopausal trial.
    Tormey C
    Recent Results Cancer Res; 1984; 96():155-65. PubMed ID: 6396769
    [No Abstract]   [Full Text] [Related]  

  • 34. 1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: a randomized controlled trial.
    Tominaga T; Kimura M; Asaga T; Yoshida M; Awane H; Koyama H; Takatsuka Y; Mitsuyama S; Ikeda T; Ogita M; Aoyama H; Sano M; Abe R; Nishi T; Wada T; Danno M; Toi M; Takashima S
    Oncol Rep; 2004 Oct; 12(4):797-803. PubMed ID: 15375502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant chemo-endocrine therapy in postmenopausal women with breast cancer and axillary-node metastases.
    Goldhirsch A; Castiglione M; Gelber RD
    Lancet; 1990 May; 335(8697):1099-100. PubMed ID: 1970400
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
    J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
    Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
    J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
    Taylor SG; Kalish LA; Olson JE; Cummings F; Bennett JM; Falkson G; Tormey DC; Carbone PP
    J Clin Oncol; 1985 Feb; 3(2):144-54. PubMed ID: 3881561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
    Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
    J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant chemotherapy with CEF versus CMF for node-positive breast cancer.
    Atkins CD
    J Clin Oncol; 1998 Dec; 16(12):3916-7. PubMed ID: 9850039
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.